Brief: Equillium Reports Third Quarter 2022 Financial Results, Provides Corporate, Clinical Updates
14/11/2022 21:16
Nov 14 (Reuters) - Equillium Inc EQ.O :
* EQUILLIUM REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND
PROVIDES CORPORATE AND CLINICAL UPDATES
* EQUILLIUM INC - INITIATED PHASE 2 STUDY OF EQ101 IN
ALOPECIA
AREATA AND PHASE 1 STUDY OF EQ102 IN HEALTHY VOLUNTEERS AND
CELIAC DISEASE PATIENTS
* EQUILLIUM - BELIEVES CASH & INVESTMENTS, ADDITIONAL CASH
ACQUIRED WITH EXPECTED CLOSING OF METACRINE DEAL, WILL BE ENOUGH
TO FUND ITS OPERATIONS INTO 2024
Source text for Eikon: ID:nBw3s43bRa
Further company coverage: EQ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Equillium
See all newsBrief: Equillium Receives Australian Regulatory Clearance To Initiate First-In-Human Clinical Trial Of Eq504
Equillium Inc reports results for the quarter ended June 30 - Earnings Summary
Equillium Q2 post narrower net loss than expected; starts R&D initiatives
Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Q1 net loss, profit miss analyst expectations